Work

Intercalating docetaxel between novel hormone therapies (NHT) abiraterone and enzalutamide in metastatic castration resistant prostate cancer (mCRPC): Does it resensitize patients to the second NHT agent?

Year: 2016

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2016.34.15_suppl.e16550

Authors: Benjamin Louis Maughan, Karim Boudadi, Rosa Maria Nadal, Emmanuel S. Antonarakis

Institutions: Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center, National Institutes of Health

Language: English

Topic: Prostate Cancer Treatment and Research

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2890747784

Cites:

Cited by: 3

Related to: 10